Position in RPRX
as of Mar 31, 2026
· filed Jun 18, 2026
Position Value
$33,060,636
+$3,924,183 QoQ
Shares Held
689,194
-8.6% QoQ
Ownership
0.120%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Pacer Advisors, Inc. holds $745,075,920 across 25 Biotechnology names. RPRX ranks #6 (4.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
358,633 | $277,094,201 | |
| 2 | INCY |
Incyte Corp
|
1,741,061 | $163,868,661 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
503,013 | $95,094,607 | |
| 4 | EXEL |
Exelixis, Inc.
|
1,549,611 | $66,462,815 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
88,863 | $39,680,884 | |
| 6 | RPRX |
Royalty Pharma plc
This page
|
689,194 | $33,060,636 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
295,524 | $19,099,716 | |
| 8 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
361,794 | $8,958,019 |
All Filings in RPRX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $33,060,636 | 689,194 | Shares | Sole | 2026-06-18 | |
| 2025-12-31 | $29,136,453 | 754,049 | Shares | Sole | 2026-02-24 | |
| 2025-09-30 | $19,812,754 | 561,586 | Shares | Sole | 2025-10-15 | |
| 2024-06-30 | $958,628 | 36,353 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $692,891 | 22,815 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $231,377 | 8,237 | Shares | Sole | 2024-01-16 | |
| 2023-09-30 | $110,188 | 4,060 | Shares | Sole | 2023-11-13 | |
| No filing history on record for this holder in this stock. | ||||||